This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Decentralising manufacturing has previously been seen as an “up-and-coming development” in the cell and gene therapy sector due to high costs associated with setting up these processes.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. The undisclosed biotech company’s option agreement with Apertura will investigate the potential of TfR1 CapX in conjunction with its payloads aimed at treating CNS disorders.
By incorporating a cell line from AvenCell into good manufacturing practice processes, ViroCell met the challenge of delivering a high-yield vector within the required timeframe. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Topic sponsors are not involved in the creation of editorial content.
Nanotein Technologies co-founder and CEO Curtis Hodge said: “Nanotein’s soluble activators are designed to improve cell therapy expansion by enhancing the quality and quantity of T cells and providing a feeder-free soluble activator for NK cell activation and expansion, addressing critical challenges in the manufacturing process.”
Porton Advanced will apply its knowledge in viral vector technology and CAR-T cell therapy process development to enhance EVA Pharma’s mission to provide safe, effective, and scalable cancer treatments. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. You will receive an email shortly.
These platforms are designed for safe drug production while allowing scaleable manufacturing processes. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Please check your inbox to download the Whitepaper. You will receive an email shortly.
This alliance seeks to bolster clinical trial capabilities through improved regulatory processes and data governance. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. How will RFK Jr’s American dream for vaccines play out?
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. AbbVie’s purchase comes just a few days after the US Food and Drug Administration (FDA) removed an access barrier for currently approved CAR-T therapies, regarded as a boost to the sector’s outlook.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. This update also suggests we may not see REMS requirements for CD19 and BCMA autologous CAR-T cell therapies in the future,” the research note added. You will receive an email shortly.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. How will RFK Jr’s American dream for vaccines play out? IZCARGO is the first drug developed with this technology and approved in Japan for treating a lysosomal storage disorder.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Sarepta confirmed it will work with the FDA to respond to requests for information while advancing the Elevidys safety labelling supplement process. Please check your inbox to download the Whitepaper.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Despite being a different drug, it is built on the same viral vector as Elevidys, a recombinant adeno-associated viral vector (AAV) called AAVrh74. You will receive an email shortly.
The company is confident that these concerns, which pertain to facilities and processes rather than product quality, can be promptly addressed. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. You will receive an email shortly.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. GlobalData is the parent company of Clinical Trials Arena.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Elsewhere in the partnership arena, AstraZeneca outlaid $5.2bn to enlist the services of China-based CSPC Pharmaceuticals. Topic sponsors are not involved in the creation of editorial content.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. His exit raises critical questions: which evidence standards will prevail: traditional or accelerated?” commented Cynthia Pussinen, CEO of Owl Bio Advisors, a life sciences consultancy group.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. How will RFK Jr’s American dream for vaccines play out? Editorial content is independently produced and follows the highest standards of journalistic integrity. You will receive an email shortly.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. You will receive an email shortly. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. Give your business an edge with our leading industry insights.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. You will receive an email shortly.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. Please check your inbox to download the Whitepaper. Shares of key sector players such as Moderna and BioNTech remain stable, with values reducing by 2.8% You will receive an email shortly.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Please check your inbox to download the Whitepaper. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Launching a new drug can be a risky business, with regulatory approval no guarantee that private, commercial, and government-funded insurers will reimburse it. Meanwhile, in Germany, the AMNOG process is conducted twelve months after the drug is launched, thus giving freedom to the company to set the drug’s price during this period.
Personally, I haven't seen this much attention in awhile about pharmacy since PillPack made strip-packaging of medications mainstream three-years ago, and am quite eager to see if this is really going to change the current paradigm of pharmacy services. One issue is that the dispensing process is not a full-proof system at the current time.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content